share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Tatsis Ourania

SEC announcement ·  Jun 4 04:12
Summary by Futu AI
Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed the sale of company shares on two separate occasions. On May 30, 2024, Tatsis sold 2,350 shares of common stock at a price of $439.11 per share. The following day, on May 31, 2024, an additional 2,250 shares were sold at $445.00 per share. The total number of shares disposed of across both transactions was 4,600, resulting in a combined market value of $2,033,158.50. After these transactions, Tatsis directly holds 51,273 shares of Vertex Pharmaceuticals.
Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed the sale of company shares on two separate occasions. On May 30, 2024, Tatsis sold 2,350 shares of common stock at a price of $439.11 per share. The following day, on May 31, 2024, an additional 2,250 shares were sold at $445.00 per share. The total number of shares disposed of across both transactions was 4,600, resulting in a combined market value of $2,033,158.50. After these transactions, Tatsis directly holds 51,273 shares of Vertex Pharmaceuticals.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.